[go: up one dir, main page]

MX2018005100A - Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders. - Google Patents

Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders.

Info

Publication number
MX2018005100A
MX2018005100A MX2018005100A MX2018005100A MX2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A
Authority
MX
Mexico
Prior art keywords
disorders
treatment
azepine compounds
otic diseases
dibenzo azepine
Prior art date
Application number
MX2018005100A
Other languages
Spanish (es)
Other versions
MX378973B (en
Inventor
Jon Seiders Thomas
Yuling Lee Catherine
Li Yiwei
Original Assignee
Inception 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inception 3 Inc filed Critical Inception 3 Inc
Publication of MX2018005100A publication Critical patent/MX2018005100A/en
Publication of MX378973B publication Critical patent/MX378973B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona el Compuesto I cristalino y el Compuesto II cristalino, composiciones farmacéuticas que comprenden uno los compuestos cristalinos adecuados para la administración intratimpánica, y métodos para tratar trastornos óticos utilizando los compuestos cristalinos y las composiciones farmacéuticas.The present description provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of the crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using crystalline compounds and pharmaceutical compositions.

MX2018005100A 2015-10-30 2016-10-27 Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders MX378973B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248625P 2015-10-30 2015-10-30
PCT/US2016/059194 WO2017075264A1 (en) 2015-10-30 2016-10-27 Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders

Publications (2)

Publication Number Publication Date
MX2018005100A true MX2018005100A (en) 2019-05-16
MX378973B MX378973B (en) 2025-03-10

Family

ID=57241193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005100A MX378973B (en) 2015-10-30 2016-10-27 Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders

Country Status (15)

Country Link
US (2) US10301266B2 (en)
EP (1) EP3368515B1 (en)
JP (1) JP6535822B2 (en)
KR (1) KR102130458B1 (en)
CN (1) CN109071450B (en)
AU (1) AU2016344138B2 (en)
CA (1) CA3002874C (en)
ES (1) ES2751082T3 (en)
IL (1) IL258660B (en)
MX (1) MX378973B (en)
NZ (1) NZ741553A (en)
PH (1) PH12018500886A1 (en)
RU (1) RU2707284C1 (en)
WO (1) WO2017075264A1 (en)
ZA (1) ZA201802576B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102130458B1 (en) 2015-10-30 2020-07-08 파이프라인 테라퓨틱스, 아이엔씨. Dibenzo azepine compound and its use in the treatment of ear diseases and ear disorders
EP3554502A4 (en) * 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
AU2019299217B2 (en) 2018-07-03 2025-04-03 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
DE602004020680D1 (en) * 2003-09-09 2009-05-28 Hoffmann La Roche THE ACTIVITY OF GAMMA-SECRETASE BLOCKING MALONAMIDE DERIVATIVES
KR100867035B1 (en) * 2003-10-06 2008-11-04 에프. 호프만-라 로슈 아게 Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
BRPI0807341A2 (en) * 2007-02-02 2014-05-20 Hoffmann La Roche 6-OXO-6,7-DI-HYDRO-5H-DIBENZO DERIVATIVES [B, D] AZEPIN-7-ILA
US7579464B2 (en) * 2007-05-25 2009-08-25 Hoffmann-La Roche Inc. Process for preparation of enantiomerically pure compounds
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US20120277199A1 (en) 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
CA2883896C (en) * 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
KR102130458B1 (en) * 2015-10-30 2020-07-08 파이프라인 테라퓨틱스, 아이엔씨. Dibenzo azepine compound and its use in the treatment of ear diseases and ear disorders
EP3554502A4 (en) * 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy

Also Published As

Publication number Publication date
NZ741553A (en) 2019-08-30
CA3002874C (en) 2020-05-05
MX378973B (en) 2025-03-10
JP6535822B2 (en) 2019-06-26
IL258660B (en) 2021-02-28
EP3368515B1 (en) 2019-07-17
CA3002874A1 (en) 2017-05-04
US10865188B2 (en) 2020-12-15
ES2751082T3 (en) 2020-03-30
RU2707284C1 (en) 2019-11-26
IL258660A (en) 2018-06-28
WO2017075264A8 (en) 2018-05-24
US10301266B2 (en) 2019-05-28
KR20180070694A (en) 2018-06-26
KR102130458B1 (en) 2020-07-08
CN109071450B (en) 2021-06-22
WO2017075264A1 (en) 2017-05-04
AU2016344138B2 (en) 2019-06-06
US20180273483A1 (en) 2018-09-27
CN109071450A (en) 2018-12-21
AU2016344138A1 (en) 2018-05-10
US20190194140A1 (en) 2019-06-27
PH12018500886A1 (en) 2018-10-29
EP3368515A1 (en) 2018-09-05
NZ750653A (en) 2021-03-26
JP2018532798A (en) 2018-11-08
ZA201802576B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
CL2018001685A1 (en) Heterocyclic compounds as immuno modulators.
ECSP20033467A (en) MACROCYCLIC COMPOUNDS TO TREAT DISEASES
GT201600147A (en) DERIVATIVE COMPOUNDS AND COMPOSITIONS OF N-AZASPIROCICLOALCANO N-HETEROARIL REPLACED TO INHIBIT THE ACTIVITY OF SHP2
CR20190318A (en) Benzooxazole derivatives as immunomodulators
ECSP16071151A (en) ROR-GAMMA DIHYDROPYRROLOPYRIDINE INHIBITORS
MX382671B (en) COMPOUNDS FOR USE IN THE TREATMENT OR AMENDING OF HUNTINGTON'S DISEASE
SV2015005066A (en) BIARIL-AMIDA COMPOUNDS AS CINASA INHIBITORS
CR20150571A (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
MX2021009673A (en) ROR-GAMMA MODULATORS.
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CO2018005315A2 (en) Modulators of the interaction of sestrina-gator2 and its uses
DOP2016000208A (en) BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
CR20150472A (en) USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS
GT201400222A (en) AGENTS TO TREAT DISORDERS THAT INVOLVE THE MODULATION OF RIANODINE RECEPTORS
CO2019011546A2 (en) Compounds and methods for the treatment of parasitic diseases
CL2017000715A1 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds
CR20160290A (en) AUTOTAXINE TETRACYCLIC INHIBITORS
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
MX2017009849A (en) COMPOSITIONS OF MONOMETILFUMARATE PROPHARMACO.
NI201600091A (en) ASYMMETRIC p-SUBSTITUTE UREAS AND MEDICAL USES OF THE SAME
CL2018001631A1 (en) Alkyl dihydroquinolinsulfonamide compounds
MX2018004868A (en) Pyrrolidine derivatives.
MX2018005100A (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders.